Latest & greatest articles for statin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on statin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on statin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for statin

1. Add a fibrate to a statin?

Add a fibrate to a statin? Add a fibrate to a statin? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Add a fibrate to a statin? View/ Open Date 2010-10 Format Metadata Abstract Do not routinely add a fibrate to a statin for patients with type 2 diabetes who are at high risk for cardiovascular events. Stength

2019 PURLS

2. Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study. (PubMed)

Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study. To investigate whether fenofibrate as add-on to statin treatment reduce persistent cardiovascular risk in adults with metabolic syndrome in a real world setting.Propensity matched cohort study.Population based cohort in Korea.29 771 adults with metabolic syndrome (≥40 years) receiving statin treatment. 2156 participants receiving combined treatment (statin plus fenofibrate (...) ) were weighted based on propensity score in a 1:5 ratio with 8549 participants using statin only treatment.Primary outcome was composite cardiovascular events including incident coronary heart disease, ischaemic stroke, and death from cardiovascular causes.The incidence rate per 1000 person years of composite cardiovascular events was 17.7 (95% confidence interval 14.4 to 21.8) in the combined treatment group and 22.0 (20.1 to 24.1) in the statin group. The risk of composite cardiovascular events

2019 BMJ

3. Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population. (PubMed)

Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population. Whether statin type influences hepatocellular carcinoma (HCC) incidence or mortality in chronic hepatitis B or C virus infection is unknown.To assess the relationship between lipophilic or hydrophilic statin use and HCC incidence and mortality in a nationwide population with viral hepatitis.Prospective propensity score (PS)-matched (...) cohort.Swedish registers, 2005 to 2013.A PS-matched cohort of 16 668 adults (8334 who initiated statin use [6554 lipophilic and 1780 hydrophilic] and 8334 nonusers) among 63 279 eligible adults.Time to incident HCC, ascertained from validated registers. Statin use was defined from filled prescriptions as 30 or more cumulative defined daily doses (cDDDs).Compared with matched nonusers, 10-year HCC risk was significantly lower among lipophilic statin users (8.1% vs. 3.3%; absolute risk difference [RD], -4.8

2019 Annals of Internal Medicine

4. Statins versus placebo for people with chronic obstructive pulmonary disease. (PubMed)

Statins versus placebo for people with chronic obstructive pulmonary disease. Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable respiratory disease. COPD exacerbations are associated with worse quality of life, increased hospitalisations, and increased mortality. Currently available pharmacological interventions have variable impact on exacerbation frequency. The anti-inflammatory effects of statins may lead to decreased pulmonary and systemic inflammation (...) , resulting in fewer exacerbations of COPD. Several observational studies have shown potential benefits of statins for patients with COPD.This review aims to evaluate available evidence on benefits and harms associated with statin therapy compared with placebo as adjunct therapy for patients with COPD. Primary objectives include the following.• To determine whether statins reduce mortality rates in COPD.• To determine whether statins reduce exacerbation frequency, improve quality of life, or improve lung

2019 Cochrane

5. Statin therapy increases lipoprotein(a) levels

Statin therapy increases lipoprotein(a) levels Lipoprotein(a) [Lp(a)] is elevated in 20-30% of people. This study aimed to assess the effect of statins on Lp(a) levels.This subject-level meta-analysis includes 5256 patients (1371 on placebo and 3885 on statin) from six randomized trials, three statin-vs.-placebo trials, and three statin-vs.-statin trials, with pre- and on-treatment (4-104 weeks) Lp(a) levels. Statins included atorvastatin 10 mg/day and 80 mg/day, pravastatin 40 mg/day (...) , rosuvastatin 40 mg/day, and pitavastatin 2 mg/day. Lipoprotein(a) levels were measured with the same validated assay. The primary analysis of Lp(a) is based on the log-transformed data. In the statin-vs.-placebo pooled analysis, the ratio of geometric means [95% confidence interval (CI)] for statin to placebo is 1.11 (1.07-1.14) (P < 0.0001), with ratio >1 indicating a higher increase in Lp(a) from baseline in statin vs. placebo. The mean percent change from baseline ranged from 8.5% to 19.6% in the statin

2019 EvidenceUpdates

6. Randomised Study of Evolocumab in Patients With Type 2 Diabetes and Dyslipidaemia on Background Statin: Primary Results of the BERSON Clinical Trial

Randomised Study of Evolocumab in Patients With Type 2 Diabetes and Dyslipidaemia on Background Statin: Primary Results of the BERSON Clinical Trial To evaluate the lipid-lowering efficacy and safety of evolocumab combined with background atorvastatin in patients with type 2 diabetes mellitus (T2DM) and hyperlipidaemia or mixed dyslipidaemia.BERSON was a double-blind, 12-week, phase 3 study (NCT02662569) conducted in 10 countries. Patients ≥18 to ≤80 years with type T2DM received atorvastatin (...) -treated patients, and there were no clinically meaningful differences in changes over time in glycaemic variables (fasting serum glucose and HbA1c) between the two groups.In patients with T2DM and hyperlipidaemia or mixed dyslipidaemia on statin, evolocumab significantly reduced LDL-C and other atherogenic lipids, was well tolerated, and had no notable impact on glycaemic measures.© 2019 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

2019 EvidenceUpdates

7. Add a fibrate to a statin?

Add a fibrate to a statin? Add a fibrate to a statin? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Add a fibrate to a statin? View/ Open Date 2010-10 Format Metadata Abstract Do not routinely add a fibrate to a statin for patients with type 2 diabetes who are at high risk for cardiovascular events. Stength

2019 PURLS

8. Statins do not increase risk of polyneuropathy: A case-control study and literature review

Statins do not increase risk of polyneuropathy: A case-control study and literature review To investigate whether there is an association between cholesterol-lowering medication use, specifically statins, and chronic polyneuropathy.A literature study was carried out to assess the current state of evidence on the association between chronic polyneuropathy and cholesterol-lowering medication use. We also conducted a prospective case-control study to compare exposure to cholesterol-lowering (...) . There was insufficient evidence that statin use is a risk factor for polyneuropathy. Our prospective case-control study included 333 patients with cryptogenic axonal polyneuropathy and 283 controls. Patients with polyneuropathy were less likely to have been exposed to statins than controls (OR 0.56, 95% confidence interval 0.34-0.95, p = 0.03). The odds of polyneuropathy decreased as exposure duration to statins increased. Cholesterol-lowering medication consisted almost exclusively of statins; therefore we only

2019 EvidenceUpdates

9. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. (Full text)

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Statin therapy has been shown to reduce major vascular events and vascular mortality in a wide range of individuals, but there is uncertainty about its efficacy and safety among older people. We undertook a meta-analysis of data from all large statin trials to compare the effects of statin therapy at different ages.In this meta-analysis, randomised trials (...) of statin therapy were eligible if they aimed to recruit at least 1000 participants with a scheduled treatment duration of at least 2 years. We analysed individual participant data from 22 trials (n=134 537) and detailed summary data from one trial (n=12 705) of statin therapy versus control, plus individual participant data from five trials of more intensive versus less intensive statin therapy (n=39 612). We subdivided participants into six age groups (55 years or younger, 56-60 years, 61-65 years, 66

2019 Lancet PubMed

10. Statins are of no benefit in acute respiratory distress syndrome

Statins are of no benefit in acute respiratory distress syndrome Statins are of no benefit in acute respiratory distress syndrome Discover Portal Discover Portal Statins are of no benefit in acute respiratory distress syndrome Published on 13 March 2018 doi: Giving statins to patients with acute respiratory distress syndrome made no difference to the number of days they spent on a ventilator. It also had no effect on mortality or the length of time spent in intensive care or in hospital (...) compared with placebo. In acute respiratory distress syndrome, the lungs become severely inflamed, fill with fluid (pulmonary oedema) and can no longer function. The person needs mechanical ventilation and is at high risk of multiple organ failure and mortality. This serious condition has high impact on both patients and NHS resources. Early studies had suggested statins may help to reverse the inflammatory process and could be a potential treatment to explore. This large, multicentre trial, funded

2019 NIHR Dissemination Centre

11. A statin drug during admission for heart surgery did not prevent an irregular heart beat

A statin drug during admission for heart surgery did not prevent an irregular heart beat A statin drug during admission for heart surgery did not prevent an irregular heart beat Discover Portal Discover Portal A statin drug during admission for heart surgery did not prevent an irregular heart beat Published on 14 July 2016 doi: The statin, rosuvastatin, taken by adults before and after heart surgery, did not prevent atrial fibrillation or heart muscle injury compared to placebo. Acute kidney (...) to reduce atrial fibrillation, nor heart muscle damage. It did, as expected, reduce “bad” cholesterol and C-reactive protein, a marker of inflammation, compared to the inactive placebo. Statins do have proven longer term benefits in reducing further damage to the coronary arteries and deaths from heart disease. Share your views on the research. Why was this study needed? Atrial fibrillation can occur in about 20% of people undergoing heart surgery and if not corrected is associated with poorer recovery

2019 NIHR Dissemination Centre

12. People take prescribed statins more reliably after discussing their advantages and disadvantages

People take prescribed statins more reliably after discussing their advantages and disadvantages People take prescribed statins more reliably after discussing their advantages and disadvantages Discover Portal Discover Portal People take prescribed statins more reliably after discussing their advantages and disadvantages Published on 11 September 2018 doi: Patients want to know more about how statins work, the reasons for prescribing them and their possible side effects. Statins lower (...) cholesterol and reduce the risk of recurrent stroke or heart attack. They also help prevent cardiovascular disease developing in people at high risk. At a population, level statins reduce the overall incidence of cardiovascular disease for people at moderate risk, but the benefits for an individual are less clear-cut. This review found that people are happy to take statins if they believe they will prolong good quality of life. Barriers include mistrust and scepticism about over-prescribing. Worry about

2019 NIHR Dissemination Centre

13. On the history of statins

On the history of statins On the History of Statins – Clinical Correlations Search On the History of Statins January 11, 2019 6 min read By David Pineles, MD Peer Reviewed With the implementation of the ACC/AHA guidelines on assessment of cardiovascular risk, [1]. Dr. John Ioadnnidis, in an article published in JAMA in February 2014, estimated that under the new guidelines approximately 1 billion people worldwide would qualify to be prescribed a statin [2]. With such a large number (...) of individuals taking this medication, it begs the question: where did statins come from? The story begins with famous German pathologist Rudolf Virchow. In the mid-19th century, Virchow discovered that cholesterol was found in the arterial walls of individuals that died from vaso-occlusive diseases such as myocardial infarction [3]. In 1913, Russian pathologist Nikolai Anitschkow, the first person to describe foam cells [4], in a brilliant study, demonstrated cholesterol’s role in the development

2019 Clinical Correlations

14. Statins for the primary prevention of cardiovascular events

Statins for the primary prevention of cardiovascular events 2019 www.kce.fgov.be KCE REPORT 306 STATINS FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR EVENTS 2019 www.kce.fgov.be KCE REPORT 306 HEALTH TECHNOLOGY ASSESSMENT STATINS FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR EVENTS AUDREY CORDON, CHRISTOPHE DE MEESTER, SOPHIE GERKENS, DOMINIQUE ROBERFROID, CHRIS DE LAET COLOPHON Title: Statins for the primary prevention of cardiovascular events Authors: Audrey Cordon (KCE), Christophe De Meester (...) Générale), Christiaan Vrints (UZA – Universitair Ziekenhuis Antwerpen) External validators: Guy De Backer (Ugent), Oscar Franco (University of Bern), Bert Vaes (KULeuven) Reported interests: All experts and stakeholders consulted within this report were selected because of their involvement in the topic of ‘Statins’. Therefore, by definition, each of them might have a certain degree of conflict of interest to the main topic of this report. Membership of a stakeholder group on which the results

2019 Belgian Health Care Knowledge Centre

15. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association (Full text)

Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association | Arteriosclerosis, Thrombosis, and Vascular Biology Search Hello Guest! Login to your account Email Password Keep me logged in Search March 2019 February 2019 January 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article (...) . Welty , Originally published 10 Dec 2018 Arteriosclerosis, Thrombosis, and Vascular Biology. 2018;39:e38–e81 Abstract One in 4 Americans >40 years of age takes a statin to reduce the risk of myocardial infarction, ischemic stroke, and other complications of atherosclerotic disease. The most effective statins produce a mean reduction in low-density lipoprotein cholesterol of 55% to 60% at the maximum dosage, and 6 of the 7 marketed statins are available in generic form, which makes them affordable

2019 American Gastroenterological Association Institute PubMed

16. What is the association between statins, when prescribed for primary or secondary prevention of cardiovascular disease, and key outcomes for community dwelling older adults living with frailty?

What is the association between statins, when prescribed for primary or secondary prevention of cardiovascular disease, and key outcomes for community dwelling older adults living with frailty? Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

17. The effects of different statins on glucose, HbA1c and new-onset diabetes: A systematic review and network meta-analysis.

The effects of different statins on glucose, HbA1c and new-onset diabetes: A systematic review and network meta-analysis. Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

18. The benefits and harms of statins and aspirin in primary prevention: a systematic review and network meta-analysis

The benefits and harms of statins and aspirin in primary prevention: a systematic review and network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

19. Statins (HMG CoA reductase inhibitors) in people with dementia, long-term benefits and harms: protocol for a systematic review

Statins (HMG CoA reductase inhibitors) in people with dementia, long-term benefits and harms: protocol for a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

20. Statin therapy for reduction of cardiovascular and limb-related events in critical limb ischemia: a systematic review and meta-analysis

Statin therapy for reduction of cardiovascular and limb-related events in critical limb ischemia: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO